(Q38191796)

30 August 2017

1 reference

title

Drugging the p53 pathway: understanding the route to clinical efficacy (English)

1 reference

Erratum: Drugging the p53 pathway: understanding the route to clinical efficacy

30 August 2017

corrigendum / erratum

0 references

author

David P. Lane

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577402%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Kian Hoe Khoo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577402%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Chandra S Verma

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577402%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

1 March 2014

1 reference

Nature Reviews Drug Discovery

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577402%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577402%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

217-236

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577402%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577402%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd4236

7 June 2020

exact match

0 references

1 reference

Regulation of the p53 pathway by ubiquitin and related proteins

31 March 2020

1 reference

The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo

31 March 2020

1 reference

31 March 2020

Surfing the p53 network

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

31 March 2020

1 reference

Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo

31 March 2020

1 reference

The pathological response to DNA damage does not contribute to p53-mediated tumour suppression

31 March 2020

1 reference

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

31 March 2020

1 reference

Tumor suppression by p53 without accelerated aging: just enough of a good thing?

31 March 2020

1 reference

mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation

31 March 2020

1 reference

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans

31 March 2020

1 reference

"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally

31 March 2020

1 reference

Tumour biology: Policing of oncogene activity by p53

31 March 2020

1 reference

Modeling the therapeutic efficacy of p53 restoration in tumors

31 March 2020

1 reference

Restoration of p53 function leads to tumour regression in vivo

31 March 2020

1 reference

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

31 March 2020

1 reference

Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence

31 March 2020

1 reference

Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression

31 March 2020

1 reference

Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages

31 March 2020

1 reference

Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control

31 March 2020

1 reference

p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa

31 March 2020

1 reference

p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

31 March 2020

1 reference

The antioxidant function of the p53 tumor suppressor

31 March 2020

1 reference

The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53.

31 March 2020

1 reference

Small molecules that bind the Mdm2 RING stabilize and activate p53.

31 March 2020

1 reference

Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest

31 March 2020

1 reference

Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2.

31 March 2020

1 reference

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

31 March 2020

1 reference

Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

31 March 2020

1 reference

Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations

31 March 2020

1 reference

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

31 March 2020

1 reference

Awakening guardian angels: drugging the p53 pathway

31 March 2020

1 reference

Translating p53 into the clinic.

31 March 2020

1 reference

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

31 March 2020

1 reference

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

31 March 2020

1 reference

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines

31 March 2020

1 reference

Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.

31 March 2020

1 reference

Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction

31 March 2020

1 reference

Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix

31 March 2020

1 reference

Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction

31 March 2020

1 reference

Chalcones: an update on cytotoxic and chemoprotective properties

31 March 2020

1 reference

Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.

31 March 2020

1 reference

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

31 March 2020

1 reference

A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.

31 March 2020

1 reference

Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

31 March 2020

1 reference

Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency

31 March 2020

1 reference

Translational approaches targeting the p53 pathway for anti-cancer therapy

31 March 2020

1 reference

Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators

31 March 2020

1 reference

A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells

31 March 2020

1 reference

Structure-based design of novel inhibitors of the MDM2-p53 interaction

31 March 2020

1 reference

Rational design and binding mode duality of MDM2-p53 inhibitors

31 March 2020

1 reference

An expeditious synthesis of the MDM2-p53 inhibitor AM-8553

31 March 2020

1 reference

Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy

31 March 2020

1 reference

Ordering of the N-terminus of human MDM2 by small molecule inhibitors

31 March 2020

1 reference

In vitro selection of mutant HDM2 resistant to Nutlin inhibition

31 March 2020

1 reference

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

31 March 2020

1 reference

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

31 March 2020

1 reference

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

31 March 2020

1 reference

MDM4 is a key therapeutic target in cutaneous melanoma

31 March 2020

1 reference

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP

31 March 2020

1 reference

Mechanism-specific signatures for small-molecule p53 activators

31 March 2020

1 reference

Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach

31 March 2020

1 reference

Siladenoserinols A–L: New Sulfonated Serinol Derivatives from a Tunicate as Inhibitors of p53–Hdm2 Interaction

31 March 2020

1 reference

Identification and characterization of the first small molecule inhibitor of MDMX

31 March 2020

1 reference

Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors

31 March 2020

1 reference

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

31 March 2020

1 reference

On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.

31 March 2020

1 reference

Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry

31 March 2020

1 reference

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

31 March 2020

1 reference

Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX

31 March 2020

1 reference

Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions

31 March 2020

1 reference

D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms

31 March 2020

1 reference

Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2

31 March 2020

1 reference

C-terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanisms

31 March 2020

1 reference

Improved eIF4E Binding Peptides by Phage Display Guided Design: Plasticity of Interacting Surfaces Yield Collective Effects

31 March 2020

1 reference

Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide

31 March 2020

1 reference

A stapled p53 helix overcomes HDMX-mediated suppression of p53.

31 March 2020

1 reference

Stapled peptides with improved potency and specificity that activate p53.

31 March 2020

1 reference

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

31 March 2020

1 reference

A spiroligomer α-helix mimic that binds HDM2, penetrates human cells and stabilizes HDM2 in cell culture

31 March 2020

1 reference

In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide

31 March 2020

1 reference

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix

31 March 2020

1 reference

A stapled BID BH3 helix directly binds and activates BAX

31 March 2020

1 reference

Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity

31 March 2020

1 reference

Adaptive evolution of p53 thermodynamic stability

31 March 2020

1 reference

Structural biology of the tumor suppressor p53.

31 March 2020

1 reference

Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease

31 March 2020

1 reference

Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles

31 March 2020

1 reference

Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.

31 March 2020

1 reference

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

31 March 2020

1 reference

Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53

31 March 2020

1 reference

Small molecule induced reactivation of mutant p53 in cancer cells

31 March 2020

1 reference

Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant

31 March 2020

1 reference

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

31 March 2020

1 reference

PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.

31 March 2020

1 reference

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer

31 March 2020

1 reference

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

31 March 2020

1 reference

Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding

31 March 2020

1 reference

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

31 March 2020

1 reference

Identification of two reactive cysteine residues in the tumor suppressor protein p53 using top-down FTICR mass spectrometry

31 March 2020

1 reference

Targeted quantitation of site-specific cysteine oxidation in endogenous proteins using a differential alkylation and multiple reaction monitoring mass spectrometry approach

31 March 2020

1 reference

Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET.

31 March 2020

1 reference

APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations

31 March 2020

1 reference

PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.

31 March 2020

1 reference

Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils

31 March 2020

1 reference

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

31 March 2020

1 reference

The missing zinc: p53 misfolding and cancer

31 March 2020

1 reference

Structure-function-rescue: the diverse nature of common p53 cancer mutants

31 March 2020

1 reference

Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.

31 March 2020

1 reference

Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.

31 March 2020

1 reference

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

31 March 2020

1 reference

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

31 March 2020

1 reference

Allele-specific p53 mutant reactivation

31 March 2020

1 reference

Introducing sense into nonsense in treatments of human genetic diseases

31 March 2020

1 reference

Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development

31 March 2020

1 reference

Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides

31 March 2020

1 reference

Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis

31 March 2020

1 reference

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

31 March 2020

1 reference

Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124

31 March 2020

1 reference

Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression

31 March 2020

1 reference

Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy

31 March 2020

1 reference

Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.

31 March 2020

1 reference

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

31 March 2020

1 reference

Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B.

31 March 2020

1 reference

Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.

31 March 2020

1 reference

Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib

31 March 2020

1 reference

Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells

31 March 2020

1 reference

DNA damage response to the Mdm2 inhibitor nutlin-3.

31 March 2020

1 reference

The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts

31 March 2020

1 reference

Structural insights into the dual-targeting mechanism of Nutlin-3

31 March 2020

1 reference

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

31 March 2020

1 reference

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

31 March 2020

1 reference

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways

31 March 2020

1 reference

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

31 March 2020

1 reference

MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.

31 March 2020

1 reference

The MDM2 gene amplification database

31 March 2020

1 reference

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma

31 March 2020

1 reference

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

31 March 2020

1 reference

Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation

31 March 2020

1 reference

p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin

31 March 2020

1 reference

Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4.

31 March 2020

1 reference

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

31 March 2020

1 reference

A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis

31 March 2020

1 reference

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models

31 March 2020

1 reference

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

31 March 2020

1 reference

Modelling Myc inhibition as a cancer therapy

31 March 2020

1 reference

Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.

31 March 2020

1 reference

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation

31 March 2020

1 reference

Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis

31 March 2020

1 reference

31 March 2020

Cancer genome landscapes

1 reference

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

31 March 2020

1 reference

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.

31 March 2020

1 reference

Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

31 March 2020

1 reference

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors

31 March 2020

1 reference

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.

31 March 2020

1 reference

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

31 March 2020

1 reference

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

31 March 2020

1 reference

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

31 March 2020

1 reference

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

31 March 2020

1 reference

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

31 March 2020

1 reference

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.

31 March 2020

1 reference

NPMc(+) AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds.

31 March 2020

1 reference

Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells

31 March 2020

1 reference

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

31 March 2020

1 reference

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

31 March 2020

1 reference

Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML

31 March 2020

1 reference

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy

31 March 2020

1 reference

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3

31 March 2020

1 reference

Hdmx modulates the outcome of p53 activation in human tumor cells

31 March 2020

1 reference

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

31 March 2020

1 reference

Inhibition of nutlin-resistant HDM2 mutants by stapled peptides

31 March 2020

1 reference

Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.

31 March 2020

1 reference

(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis

31 March 2020

1 reference

Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.

31 March 2020

1 reference

Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia

31 March 2020

1 reference

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.

31 March 2020

1 reference

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

31 March 2020

1 reference

Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.

31 March 2020

1 reference

Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53.

31 March 2020

1 reference

Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.

31 March 2020

1 reference

1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.

31 March 2020

1 reference

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.

31 March 2020

1 reference

Acetylation of p53 inhibits its ubiquitination by Mdm2.

31 March 2020

1 reference

BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death

31 March 2020

1 reference

Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.

31 March 2020

1 reference

Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells

31 March 2020

1 reference

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

31 March 2020

1 reference

Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins

31 March 2020

1 reference

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

31 March 2020

1 reference

ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.

31 March 2020

1 reference

Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway

31 March 2020

1 reference

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status

31 March 2020

1 reference

A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.

31 March 2020

1 reference

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

31 March 2020

1 reference

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy

31 March 2020

1 reference

Cancer. p53, guardian of the genome

31 March 2020

1 reference

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells

31 March 2020

1 reference

Cyclotherapy: opening a therapeutic window in cancer treatment

31 March 2020

1 reference

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

31 March 2020

1 reference

p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53

31 March 2020

1 reference

p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells

31 March 2020

1 reference

Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA.

31 March 2020

1 reference

DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis.

31 March 2020

1 reference

Life or death: p53-induced apoptosis requires DNA binding cooperativity.

31 March 2020

1 reference

p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo.

31 March 2020

1 reference

ASPP proteins specifically stimulate the apoptotic function of p53

31 March 2020

1 reference

iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53.

31 March 2020

1 reference

The expression of iASPP in acute leukemias

31 March 2020

1 reference

iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe

31 March 2020

1 reference

31 March 2020

Modes of p53 regulation

1 reference

ATM phosphorylation of Mdm2 Ser394 regulates the amplitude and duration of the DNA damage response in mice

31 March 2020

1 reference

Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding

31 March 2020

1 reference

Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.

31 March 2020

1 reference

Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2

31 March 2020

1 reference

Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation

31 March 2020

1 reference

A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX.

31 March 2020

1 reference

In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute

31 March 2020

1 reference

Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim

31 March 2020

1 reference

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

31 March 2020

1 reference

p53 has a direct apoptogenic role at the mitochondria

31 March 2020

1 reference

Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis

31 March 2020

1 reference

Non-cell-autonomous tumor suppression by p53.

31 March 2020

1 reference

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

31 March 2020

1 reference

Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

31 March 2020

1 reference

31 March 2020

1 reference

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

31 March 2020

1 reference

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

31 March 2020

1 reference

PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.

31 March 2020

1 reference

12 December 2020

New insights into p53 based therapy

1 reference

12 December 2020

The restriction point of the cell cycle

1 reference

12 December 2020

The p53 response to ionising radiation in adult and developing murine tissues.

1 reference

12 December 2020

Exploiting cancer cell cycling for selective protection of normal cells.

1 reference

12 December 2020

Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics.

1 reference

12 December 2020

Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

1 reference

12 December 2020